



**GENERATION, PROPAGATION AND CHARACTERIZATION OF SECOND  
AND FULL-TERM AMNIOTIC FLUID-DERIVED MESENCHYMAL STEM  
CELL**

By

**PEYMAN GHORAISHIZADEH**

**Thesis Submitted to the School of Graduate Studies,  
Universiti Putra Malaysia, in Fulfillment of the  
Requirements for the Degree of Master of Science**

**May 2016**

**FPSK(m) 2019 60**

## **COPYRIGHT**

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia

## **DEDICATION**

This thesis is dedicated to my dearest mother and brother for the understanding and encouragement they provided during all these years of the study



Abstract of the thesis presented to the Senate of Universiti Putra Malaysia in  
fulfillment of the requirement for the degree of Master of Science

**GENERATION, PROPAGATION AND CHARACTERIZATION OF SECOND  
AND FULL-TERM AMNIOTIC FLUID-DERIVED MESENCHYMAL STEM  
CELL**

By

**PEYMAN GHORAISHIZADEH**

**May 2016**

**Chair: Thilakavathy Karupppiah, PhD  
Faculty: Medicine and Health Sciences**

Mesenchymal stem cells (MSCs) are multipotent stem cells that are highly proliferative with the ability of self-renewal and the potential to differentiate into various cell lineages. The differentiation potential, self-renewability, immune-suppression properties and ease for genetic modification make them a frontier candidate for regenerative medicine, cell and gene therapy. To date, bone marrow (BM) is the most accessible source of MSCs for isolation, but BM aspiration is very invasive and a painful procedure. Although the success rate of stem cell retrieval and their expansion is high in adult bone marrow samples, certain conditions can limit their accessibilities. For instance, in some clinical cases such as bone marrow failure, aplastic anaemia, leukaemia or chemotherapy, patients often encounter complications of inadequate cellular fractions in their bone marrow aspiration, for these patients, the only alternative source of MSCs would be a second party donor. Most of the time, there are difficulties in finding the suitable donor. Moreover, the number and differentiation capacity of MSCs decrease significantly with ageing. Altogether, these necessitate a need to search for alternative sources of MSCs for research and therapeutics application. Human amniotic fluid cells (hAFCs) have been used as a diagnostic tool for prenatal diagnosis and they have been found to be a rich source of progenitor/stem cells. Human amniotic fluid (hAF) is usually considered as clinical wastes and inevitably discarded during amniocentesis, caesarean (c-section) and normal delivery. Two main populations of stem cells that can be isolated from human amniotic fluid, are amniotic fluid mesenchymal stem cells (hAF-MSCs) and amniotic fluid stem cells.

In current study hAF-MSCs are isolated from amniocentesis and caesarean samples and propagated in vitro using different growth medium. The study performed a comparative analysis for the effect of different media components on the properties of MSCs (cell morphology, cell growth, surface markers, colony forming unit assay and differentiating potential). The hAF-MSCs were characterized using flow cytometry technique and screen a panel of cell surface markers. In conclusion, hAF-MSCs were successfully generated from the amniocentesis and cesarean amniotic fluid samples, without any significant characteristic difference between hAF-MSCs derived from the two gestation periods. XSFM was found to be the best medium for the generation and propagation of the hAF-MSCs in comparison to the DMEM-FBS and DMEM-HS. Therefore, this study suggests that the cesarean amniotic fluid, a waste product during delivery is feasible to generate xenogenic free hAF-MSCs for safe therapeutic application and possible hAF-MSCs\banking.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia  
sebagai memenuhi keperluan untuk ijazah Master Sains

**PENJANAAN, PEMBIAKAN, DAN PENCIRIAN BAGI PERINGKAT KEDUA  
DAN FASA PENUH SEL INDUK MESENKIMA YANG DIPEROLEHI  
DARIPADA CECAIR AMNION**

Oleh

**PEYMAN GHORAISHIZADEH**

**Mei 2016**

**Pengerusi: Thilakavathy Karuppiah, PhD**

**Fakulti: Perubatan dan Sains Kesihatan**

Sel induk mesenkima merupakan sel induk multipotensi yang mempunyai pembiakan yang aktif, memiliki keupayaan perubahan diri yang tinggi dan mampu membezakan dirinya kepada sel yang bercirikan mesoderma. Potensi membezakan diri, keupayaan pembaharuan diri, kegiatan immunotindasan dan kemudahan untuk modifikasi genetik oleh MSC menjadikan ia sebagai calon yang berpotensi dalam perubatan generasi semula dan sel atau gen terapi. Pada ketika ini, sumsum tulang belakang (BM) adalah sumber MSC yang paling mudah untuk isolasi, tetapi aspirasi BM adalah sangat invasif dan prosedur mendapatkan sumsum tulang adalah agak menyakitkan. Meskipun kejayaan pengambilan sel induk dan process memperbanyak kuantiti sel adalah tinggi daripada sampel sumsum tulang dewasa, tetapi pada kondisi tertentu keupayaan sel ini adalah terhad. Contohnya di dalam kes klinikal di mana terdapat kegagalan sumsum tulang, anemia aplastik, leukemia atau kemoterapi di mana pesakit sering mengalami komplikasi pecahan sel selular yang tidak memadai dengan aspirasi sumsum tulang mereka. Oleh itu satu-satunya sumber alternatif MSC daripada sumsum tulang dewasa, adalah penderma daripada pihak kedua. Kebiasaan untuk mendapat penderma yang sesuai adalah sangat susah. Selain itu jumlah dan kapasiti untuk proses MSC membezakan dirinya akan menurun secara signifikan dengan pertambahan umur. Penyelesaian kepada permasalahan ini, adalah mencari sumber alternatif MSC yang baru untuk tujuan ujikaji dan aplikasi terapeutik. Penemuan sel cairan amnion manusia (hAFCS) telah digunakan sebagai sumber untuk diagnosis prenatal di mana terdapat penemuan yang mengatakan hAFCS ini kaya dari progenitor/sel induk. Cairan ketuban manusia (haf) biasanya dianggap sebagai sisa klinikal dan ia akan dibuang semasa amniosentesis, caesar (c-section) dan persalinan normal. Dua populasi utama sel induk yang dapat diisolasi dari cairan ketuban manusia,

adalah sel induk mesenigma cairan ketuban (hAF-MSCs) dan sel induk mesenigma cairan amnion.

Di dalam kajian ini, hAF-MSCs diisolasi dari amniosentesis dan sampel caesarean, di mana hAF-MSCs ditumbuhkan secara *in vitro* dengan menggunakan media pertumbuhan yang berbeza. Di dalam kajian ini analisis perbandingan telah dilakukan untuk mengetahui kesan komponen media yang berbeza pada sifat-sifat MSC (morfologi sel, pertumbuhan sel, penanda permukaan, uji unit pembentuk koloni dan potensi membezakan diri hAF-MSCs daripada sel yang lain). Analisis penanda permukaan sel hAF-MSCs adalah menggunakan teknik aliran sitometer dan penyaring panel penanda permukaan sel. Kesimpulannya, HAF-MSCs berjaya dihasilkan daripada sampel cairan amniosentesis dan caesarean amniotik, tanpa sebarang perbezaan ciri-ciri penting antara hAF-MSC yang diperoleh dari dua tempoh kehamilan. XSFM didapati medium terbaik untuk menghasilkan dan pertumbuhan hAF-MSCs berbanding dengan DMEM-FBS dan DMEM-HS. XSFM adalah penemuan yang terbaik untuk media penjanaan dan pertumbuhan hAF-MSC dibandingkan dengan DMEM-FBS dan DMEM-HS. Oleh itu , penelitian di dalam kajian ini menyarankan cairan ketuban caesarean yang dianggap sisa klinikal sepanjang proses kelahiran adalah dianggap paling layak untuk menghasilkan ,xenogenic hAF-MSCs untuk aplikasi terapeutik yang selamat dan kemungkinan juga untuk proses pengumpulan bank hAF-MSCs.

## **ACKNOWLEDGEMENTS**

I owe a depth of gratitude to everyone, without whom this work would not have been possible. First of all, I would like to express my sincere thanks to my supervisor Dr. Thilakavathy Karuppiah who supported and helped me from the very beginning of my studies. I would like to thank Dr. Rajesh Ramasamy and Dr. Zulida Rejali for their support and encouragement, as well as for, spending their valuable time in reading and correcting mistakes in the earlier drafts.

I would also like to thank Dr. Gurbind Singh who has given his suggestions and ideas during the progress of this project and to all my friends and course-mates, thanks for all the assistance and support that you have rendered whenever possible.

Last but not least, I would like to thank my mother and my best friends, my dear Roya, Hamid and Ali for the encouragement and moral support. I would like to thank my dear brother, Saman, who supported me with his kindness all these years. Without them, I will never be able to complete this project. Thank you.

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

**Thilakavathy Karuppiah, PhD**

Associate Professor

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Chairman)

**Zulida Rajali, PhD**

Senior Medical Lecturer

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Member)

**Rajesh Ramasamy, PhD**

Associate Professor

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Member)

---

**ROBIAH BINTI YUNUS, PhD**

Professor and Dean

School of Graduate Studies

Universiti Putra Malasyia

Date: 12 September 2019

### **Declaration by Graduate Student**

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- There is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Name and Matric No.: Peyman Ghoraishizadeh

## **Declaration by Members of Supervisory Committee**

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: \_\_\_\_\_

Name of

Chairman of

Supervisory

Committee: Associate Professor, Dr. Thilakavathy Karuppiah

Signature: \_\_\_\_\_

Name of

Member of

Supervisory

Committee: Dr. Zulida Rajali

Signature: \_\_\_\_\_

Name of

Member of

Supervisory

Committee: Associate Professor, Dr., Rajesh Ramasamy

## TABLE OF CONTENTS

	<b>Page</b>
<b>ABSTRACT</b>	i
<b>ABSTRAK</b>	iii
<b>ACKNOWLEDGEMENTS</b>	v
<b>APPROVAL</b>	vi
<b>DECLARATION</b>	viii
<b>LIST OF TABLES</b>	xiii
<b>LIST OF FIGURES</b>	xiv
<b>LIST OF ABBREVIATIONS</b>	xv
<b>CHAPTER</b>	
<b>1 INTRODUCTION</b>	1
1.1 Background of Study	1
1.2 Hypotheses of the Study	3
1.3 Objectives of the Study	3
<b>2 LITERATURE REVIEW</b>	4
2.1 Stem Cells	4
2.1.1 Biology	4
2.1.2 Different types of Stem Cells	4
2.2 Mesenchymal Stem Cells	6
2.2.1 Biology and Definition	6
2.2.2 Sources of MSCs	6
2.3 Characterisation of MSCs	8
2.3.1 Immunophenotyping	8
2.3.2 Differentiation Potential	11
2.3.3 Self-Renewal of MSCs	13
2.3.4 Immunological Specifications of MSCs	13
2.4 Therapeutic Potentials of MSCs	15
2.5 Amniotic Fluid	18
2.6 Cells and Stem Cells in Amniotic Fluid	19
2.7 Isolation and Expansion of Amniotic Fluid	20
Mesenchymal Stem Cells	
2.8 Comparison of Amniotic Fluid Mesenchymal Stem Cells with Adult and Neonatal Derived Mesenchymal Stem Cells	21
2.9 Current Status of Stem Cell Application in Cell Therapy in Malaysia and Internationally.	22
<b>3 METHODOLOGY</b>	24
3.1 Study Subjects	24
3.2 Sample Preparation	24
3.2.1 Amniocentesis sample	24
3.2.2 Caesarean sample	25
3.3 Mesenchymal Stem Cell culture	25
3.3.1 Media used for cell culturing	25

3.3.2	Colony forming unit fibroblast assay (CFU-F assay)	26
3.3.3	Population doubling time (PDT)	26
3.4	Characterization of Mesenchymal stem cells	27
3.4.1	Immunophenotyping	27
3.5	Differentiation	28
3.5.1	Adipogenesis	29
3.5.2	Oil Red Staining	29
3.5.3	Osteogenesis Differentiation	29
3.5.4	Alizarin Red Staining	30
3.5.5	Chondrogenesis Differentiation	30
3.5.6	Alician Blue Staining	30
3.6	Statistical Analysis	30
<b>4</b>	<b>FINDINGS</b>	31
4.1	Generation and Expansion of hAF-MSCs	31
4.1.1	Generation and Expansion of hAF-MSCs Derived from Amniocentesis	31
4.2	Colony forming unit fibroblast assay (CFU-F) assay	35
4.3	Population doubling time (PDT)	36
4.4	Generation and expansion of hAF-MSCs derived from caesarean samples	38
4.5	Colony forming unit fibroblast assay (CFU-F) assay	42
4.6	Population doubling time (PDT)	43
4.7	Characterization of hAF-MSCs	45
4.7.1	Characterisation of hAF-MSCs derived from amniocentesis samples	45
4.7.2	Differentiation	50
4.7.3	Characterisation of hAF-MSCs derived from caesarean samples	55
4.8	Comparison of hAF-MSCs obtained from amniocentesis amniotic fluid and caesarean procedures.	55
4.8.1	CFU-assay	65
4.8.2	Population doubling time (PDT)	66
4.8.3	Immunophenotyping	67
4.8.4	Differentiation to adipogenesis, osteogenesis and chondrogenesis	70
<b>5</b>	<b>DISCUSSION</b>	70
5.1	Generation and expansion of human amniotic fluid	72
5.2	Characterisation of hAF-MSCs	72
5.3	Comparison between hAF-MSCs derived from amniocentesis and caesarean specimens	75
<b>6</b>	<b>SUMMARY, CONCLUSION AND RECOMMENDATIONS FOR FUTURE RESEARCH</b>	75
6.1	Conclusion	75

6.2	Limitation of study	76
6.3	Future recommendation	76
<b>REFERENCES</b>		77
<b>APPENDICES</b>		102
<b>BIODATA OF STUDENT</b>		107

## LIST OF TABLES

<b>Table</b>		<b>Page</b>
2.1	Bone Marrow derived MSCs Markers	9
3.1	List of antibodies used for immnophenotyping	28
4.1	Numbers of colonies in different passages and different media	36
4.2	PDT in XSFM and DMEM-FBS in different passages	37
4.3	Expression of surface markers of hAFMSCs in XSFM and DMEM-FBS in different passages.	43
4.4	Percentage of differentiation to mesodermal lineages in DMEM-FBS and XSFM in different	44
4.5	Numbers of colonies in different passages and different media	50
4.6	PDT in XSFM and DMEM-FBS in different passages	55
4.7	Expression of surface markers of hAFMSCs in XSFM and DMEM-FBS in different passages.	61
4.8	Percentage of differentiation to mesodermal lineages in DMEM-FBS and XSFM in different passages	65


## LIST OF FIGURES

<b>Figure</b>		<b>Page</b>
2.1	Role of interferon gamma in immune suppression	14
2.2	Way of dual function of mesenchymal stem cell in treatment of disease,	18
4.1	Morphology of confluent cells in P0	31
4.2	Morphology of cells in P1 DMEM-HS	32
4.3	Morphology of cells in P1 DMEM-FBS	33
4.4	Morphology of cells in XSFM at passages 3, 5, 7.	34
4.5	CFU-F assay of hAFMSCs in XSFM and DMEM-FBS in different passages	35
4.6	Cell count in XSFM and DMEM-FBS in different passages	37
4.7	Immunophenotyping of hAFMSCs (P3) in DMEM-FBS and XSFM by flowcytometry analysis	38
4.8	Differentiation potential of amniotic fluid mesenchymal stem cells into mesodermal lineages	39
4.9	Morphology of confluent cells in P0	40
4.10	Morphology of cells in P1 DMEM-HS,	41
4.11	Morphology of cells in P1 DMEM-FBS	42
4.12	Morphology of cells in XSFM in passages 3, 5, 7.	44
4.13	CFU-F assay of hAFMSCs in XSFM and DMEM-FBS in different passages	49
4.14	Cell count in XSFM and DMEM-FBS in different passages	54
4.15	Immunophenotyping of hAFMSCs (P3) in DMEM-FBS and XSFM by flowcytometry analysis	60
4.16	Differentiation potential of amniotic fluid mesenchymal stem cells into mesodermal lineages	64
4.17	CFU-F assay of hAFMSCs from 2nd and 3rd trimester samples	66
4.18	Population doubling time (PDT) of hAFMSCs from 2nd and 3rd trimester	67
4.19	Adipocytes, osteocytes and chondrocytes differentiation percentage of hAFMSCs from 2nd and 3rd trimester samples cases	69

## LIST OF ABBREVIATIONS

AF	Amniotic Fluid
AFKL	Amniotic Fluid c-Kit, Lin
AF-MSCs	Amniotic Fluid Mesenchymal stem cells
bFGF	Basic Fibroblast Growth Factor
BM	Bone Marrow
BM-MSCs	Bone Marrow Mesenchymal Stem Cells
BD	BECTON DICKINSON
CD	Cluster of differentiation
CFU	Colony-forming units
CT	Culture Time
CBT	Cord Blood Transplant
CBF1	Core Binding Factor 1
DMEM	Dulbecco's Modified Eagle Medium
EAE	Experimental Autoimmune Encephalomyelitis
EDTA	Ethylene diaminetetra acetic acid
EGF	Epidermal Growth Factor
EPC	Endothelial Progenitor Cells
FACS	Fluorescence Activated Cell Storing
FBS	Fetal Bovine Serum
F2R	Coagulation Factor II Receptor
F2RL	Coagulation Factor II Receptor-Like
FITC	Fluorescein Isothiocyanate
GD2	Ganglioside 2
GFP	Green Fluorescence Protein
HAF	Human Amniotic Fluid
HAFC	Human Amniotic Fluid Cells
hAF-MSCs	Human Amniotic Fluid Mesenchymal Stem Cells
HLA	Human Leukocyte Antigen
HS	Human Serum
IFN- $\gamma$	Interferon Gamma
IL1-R	Interleukin Receptor 1
INRs	Immune non-responders
ICM	Inner Cell Mass
iPSCs	Induced Pluripotent Stem Cells
KIRs	Killer Immunoglobulin-like receptors
MACS	Magnetic Activated Cell Storing
MMP2	Matrix Metalloproteinase 2
MSCs	Mesenchymal stem cells
MS	Multiple Sclerosis
PDGF	Platelet Derived Growth Factor
PLA2G10	Phospholipase A2, group X
PDT	Population Doubling Time
PDN	Population Doubling Number
PRP	Platlet Rich Plasma

PE	Phycoerythrin
ssDNA	Single-Stranded DNA
TNF	Tumor Necrosis Factor
TGFB1	Transforming Growth Factor B1
VWF	Van – Willebrand factor
VEGF	Vascular Endothelial Growth Factor
XSFM	Xeno-and Serum-Free Media



# CHAPTER 1

## INTRODUCTION

### 1.1 Background of Study

Mesenchymal Stem cells (MSCs) were isolated and described for the first time by Friedenstein and Petrakova from rat bone marrow (BM) (Friedenstein, Piatetzky-Shapiro, & Petrakova, 1966). MSCs are also referred to as BM stromal cells, BM stromal stem cells, colony-forming fibroblastic cells and mesenchymal progenitor cells (Baksh, Song, & Tuan, 2004) (Kemp, Hows, & Donaldson, 2005). MSCs are highly proliferative multipotent stem cells with the ability of self-renewal and the potential to differentiate into various cell lineages such as adipocytes, chondrocytes, osteoblasts, endothelial cells, cardiac myocytes, nerve cells, hepatocytes and pancreas cells (Kemp et al., 2005); A Alhadlaq & Mao, 2003; (Pittenger, 1999a) (Kim et al., 2014); (Jiang, Vaessen, et al., 2002)A Alhadlaq & Mao, 2003; Xiang et al., 2007; Kim et al., 2014). Differentiation potential of these cells was observed in *in-vivo*, *in-vitro* and *ex-vivo* cultures. Their differentiation potential, self-renewability, immunosupresant properties (Le Blanc, Tammik, Rosendahl, Zetterberg, & Ringdén, 2003) and ease acceptive for genetic modification (Chan et al., 2005) makes them a frontier candidate for regenerative medicine, cell and gene therapy (Amara, Touati, Beaune, & de Waziers, 2014).

To date, BM is the most accessible source of MSCs for isolation. Indeed, BM contributes to most of the research and development on MSC biology. Most work concerning MSCs are done exclusively on adult bone marrow MSC (BM-MSCs), however, BM aspiration is an invasive and painful procedure which is at risk for infection, excessive bleeding and other complications (Duscher et al., 2014). Although the success rate of stem cell retrieval and their expansion is high in adult bone marrow samples, certain conditions can limit their accessibility. For instance, in some clinical cases such as bone marrow failure, aplastic anaemia, leukaemia or chemotherapy, patients often encounter complications of inadequate cellular fractions in their bone marrow aspiration. For these patients, the only alternative source of MSCs would be a second party donor. Most of the time, there are difficulties in finding the suitable donor. Moreover, the number and differentiation capacity of MSC decreased significantly with ageing (Makhluf, Mueller, Mizuno, & Glowacki, 2000; Mueller & Glowacki, 2001). Altogether, these necessitate a need to search for alternative sources of MSCs for research and therapeutic applications.

Mesenchymal stem cells have been isolated from other sources such as fat tissues (Ghorbani, Jalali, & Varedi, 2014), endometrium (Schüring et al., 2011), appendix (De Coppi et al., 2006) and synovium (D.-H. Lee et al., 2011); especially from tissue of fetal origin like cord blood (CB) (Divya et al., 2012), chorionic villi (Igura et al.,

2004) umbilical cord (UC) (Sarugaser, Lickorish, Baksh, Hosseini, & Davies, 2005) (Vellasamy, Sandrasaigaran, Vidyadarshan, George, & Ramasamy, 2012) and amniotic fluid (AF) (De Coppi, Bartsch, et al., 2007; Peng, Wang, Chao, & Chang, 2007; Gosden, 1983).

In the last 7 years, human amniotic fluid cells (hAFCs) have been used as a diagnostic tool for prenatal diagnosis (Chadefaux-Vekemans et al., 2006) (Bossolasco et al., 2006) and they were found to be a rich source of progenitor/stem cells (De Coppi, Bartsch, et al., 2007) (Ditadi et al., 2009). Human amniotic fluid (hAF) is usually considered as clinical waste and is inevitably discarded during amniocentesis, caesarean and normal delivery. Two main populations of stem cells isolated from hAF are amniotic fluid mesenchymal stem cells (hAF-MSCs) and amniotic fluid stem cells (hAFSc) (M.-S. Tsai, Lee, Chang, & Hwang, 2004; De Coppi, Bartsch, et al., 2007). hAF-MSCs are ample and can be easily obtained from small volume (2-5 ml) of AF (Cananzi, Atala, & De Coppi, 2009), (Nadri & Soleimani, 2007). The percentage of their population is estimated at 0.9-1.5%, and can be easily cultured (Kunisaki et al., 2007). Transcriptome analysis of AFMSCSs show up-regulation involved in uterine maturation and contraction such as PLA2G10 and in signal transduction pathways such as F2R, F2RL. These findings suggest an important role of AFMSCs in regulating the interactions between the uterus and the foetus during pregnancy (T.-H. Wang, Lee, & Hwang, 2011).

Thus, the early phase of this project focused on the generation of MSCs from hAF collected from different trimesters (second and third), where the generated cells were characterised using a panel of cell surface markers and their ability to differentiate the three lineages (adipocytes, osteoblasts and chondrocytes).

Propagation of human and animal cells in lab conditions requires appropriate culture media. The culture medium provides vital nutrients for cell growth, proliferation and metabolism. Basal media are mostly supplemented with fetal bovine serum (FBS), which enhance cell growth and proliferation (Price & Gregory, 1982), (Wessman & Levings, 1999). FBS contains rich content of growth factors and low gamma globulin content, these properties make it the standard supplement of cell culture media but it has some disadvantages, such as causes of the risk of transmission of animal pathogens and xenogenic immune reactions (Eloit, 1999) (Dormont, 1999). In this project, the effects of human serum (HS), FBS and xeno-and serum-free media (XSF) on MSC properties (cell morphology, cell growth, surface markers and differentiating potential) were evaluated.

## 1.2 Hypotheses of the Study

The hypotheses of this study are:

- i. MSCs can be generated from human amniotic fluid (hAF) obtained from amniocentesis and caesarean procedures.

- ii. hAFMSCs can be generated using xeno- and serum-free medium and media containing human serum and FBS.

### **1.3 Objectives of the Study**

The general objective of this project is:

To generate and characterize hAF-MSCs harvested from second and full-term hAF grown in different culture media.

The specific objectives of this study are:

- i. To generate and propagate second trimester and full trimester hAF-derived hAF-MSCs in different culture media
- ii. To characterize hAF-MSCs by immunophenotyping and trilineages differentiation assay.
- iii. To compare the hAF-MSCs generated from second trimester hAF samples collected from amniocentesis and caesarean procedure.

## REFERENCES

- Akiyama, K., You, Y.-O., Yamaza, T., Chen, C., Tang, L., Jin, Y., ... Shi, S. (2012). Characterization of bone marrow derived mesenchymal stem cells in suspension. *Stem Cell Research & Therapy*, 3(5), 40. <http://doi.org/10.1186/scrt131>
- Alhadlaq, A., & Mao, J. J. (2003). Tissue-engineered neogenesis of human-shaped mandibular condyle from rat mesenchymal stem cells. *Journal of Dental Research*, 82(12), 951–6. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/14630893>
- Alhadlaq, A., & Mao, J. J. (2004). Mesenchymal stem cells: isolation and therapeutics. *Stem Cells and Development*, 13(4), 436–48. <http://doi.org/10.1089/1547328041797552>
- Alt, E. U., Senst, C., Murthy, S. N., Slakey, D. P., Dupin, C. L., Chaffin, A. E., ... Izadpanah, R. (2012). Aging alters tissue resident mesenchymal stem cell properties. *Stem Cell Research*, 8(2), 215–25. <http://doi.org/10.1016/j.scr.2011.11.002>
- Amara, I., Touati, W., Beaune, P., & de Waziers, I. (2014). Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors. *Biochimie*, 105, 4–11. <http://doi.org/10.1016/j.biochi.2014.06.016>
- Baghaban Eslaminejad, M., Jahangir, S., & Aghdam, N. (2011). Mesenchymal stem cells from murine amniotic fluid as a model for preclinical investigation. *Archives of Iranian Medicine*, 14(2), 96–103. <http://doi.org/011142/AIM.006>
- Baksh, D., Song, L., & Tuan, R. S. (2004). Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. *Journal of Cellular and Molecular Medicine*, 8(3), 301–316. <http://doi.org/10.1111/j.1582-4934.2004.tb00320.x>

- Barlow, S., Brooke, G., Chatterjee, K., Price, G., Pelekanos, R., Rossetti, T., ... Atkinson, K. (2008). Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. *Stem Cells and Development*, 17(6), 1095–107. <http://doi.org/10.1089/scd.2007.0154>
- Beall, M. H., van den Wijngaard, J. P. H. M., van Gemert, M. J. C., & Ross, M. G. (2007). Regulation of amniotic fluid volume. *Placenta*, 28(8-9), 824–32. <http://doi.org/10.1016/j.placenta.2006.12.004>
- Beltrami, A. P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., ... Anversa, P. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. *Cell*, 114(6), 763–776. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/14505575>
- Bieback, K. (2004). Critical Parameters for the Isolation of Mesenchymal Stem Cells from Umbilical Cord Blood. *Stem Cells*, 22(4), 625–634. <http://doi.org/10.1634/stemcells.22-4-625>
- Blum, B., & Benvenisty, N. (2008). The tumorigenicity of human embryonic stem cells. *Advances in Cancer Research*, 100, 133–158. [http://doi.org/10.1016/S00065-230X\(08\)00005-5](http://doi.org/10.1016/S00065-230X(08)00005-5)
- Bossolasco, P., Montemurro, T., Cova, L., Zangrossi, S., Calzarossa, C., Buiatotis, S., ... Lazzari, L. (2006). Molecular and phenotypic characterization of human amniotic fluid cells and their differentiation potential. *Cell Research*, 16(4), 329–36. <http://doi.org/10.1038/sj.cr.7310043>
- Bussolati, B., & Camussi, G. (2015). Therapeutic use of human renal progenitor cells for kidney regeneration. *Nature Reviews. Nephrology*, 11(12), 695–706. <http://doi.org/10.1038/nrneph.2015.126>
- Cananzi, M., Atala, A., & De Coppi, P. (2009). Stem cells derived from amniotic fluid: new potentials in regenerative medicine. *Reproductive Biomedicine Online*, 18 Suppl 1, 17–27. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/19281660>

Chadefaux-Vekemans, B., Rabier, D., Cadoudal, N., Lescoat, A., Chabli, A., Aupetit, J., ... Oury, J. F. (2006). Prenatal diagnosis of some metabolic diseases using early amniotic fluid samples: report of a 15 years, experience. *Prenatal Diagnosis*, 26(9), 814–8. <http://doi.org/10.1002/pd.1509>

Chan, J., O'Donoghue, K., de la Fuente, J., Roberts, I. A., Kumar, S., Morgan, J. E., & Fisk, N. M. (2005). Human fetal mesenchymal stem cells as vehicles for gene delivery. *Stem Cells (Dayton, Ohio)*, 23(1), 93–102. <http://doi.org/10.1634/stemcells.2004-0138>

Chen, G., Yue, A., Ruan, Z., Yin, Y., Wang, R., Ren, Y., & Zhu, L. (2014). Human umbilical cord-derived mesenchymal stem cells do not undergo malignant transformation during long-term culturing in serum-free medium. *PloS One*, 9(6), e98565. <http://doi.org/10.1371/journal.pone.0098565>

Chen, J., Li, Y., Hao, H., Li, C., Du, Y., Hu, Y., ... Chen, L. (2015). Mesenchymal Stem Cell Conditioned Medium Promotes Proliferation and Migration of Alveolar Epithelial Cells under Septic Conditions In Vitro via the JNK-P38 Signaling Pathway. *Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology*, 37(5), 1830–1846. <http://doi.org/10.1159/000438545>

Chen, J.-Y., Mou, X.-Z., Du, X.-C., & Xiang, C. (2015). Comparative analysis of biological characteristics of adult mesenchymal stem cells with different tissue origins. *Asian Pacific Journal of Tropical Medicine*, 8(9), 739–746. <http://doi.org/10.1016/j.apjtm.2015.07.022>

Chen, X., Xu, H., Wan, C., McCaigue, M., & Li, G. (2006). Bioreactor expansion of human adult bone marrow-derived mesenchymal stem cells. *Stem Cells (Dayton, Ohio)*, 24(9), 2052–2059. <http://doi.org/10.1634/stemcells.2005-0591>

Chijimatsu, R., Ikeya, M., Yasui, Y., Ikeda, Y., Ebina, K., Moriguchi, Y., ... & Nakamura, N. (2017). Characterization of mesenchymal stem cell-like cells derived from human iPSCs via neural crest development and their application for osteochondral repair. *Stem cells international*, 2017. <https://doi.org/10.1155/2017/1960965>

- Chong, P.-P., Selvaratnam, L., Abbas, A. A., & Kamarul, T. (2012). Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells. *Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society*, 30(4), 634–642. <http://doi.org/10.1002/jor.21556>
- Da Sacco, S., Sedrakyan, S., Boldrin, F., Giuliani, S., Parnigotto, P., Habibian, R., ... Perin, L. (2010). Human amniotic fluid as a potential new source of organ specific precursor cells for future regenerative medicine applications. *The Journal of Urology*, 183(3), 1193–1200. <http://doi.org/10.1016/j.juro.2009.11.006>
- De Coppi, P., Bartsch, G., Siddiqui, M. M., Xu, T., Santos, C. C., Perin, L., ... Atala, A. (2007). Isolation of amniotic stem cell lines with potential for therapy. *Nature Biotechnology*, 25(1), 100–106. <http://doi.org/10.1038/nbt1274>
- De Coppi, P., Callegari, A., Chiavegato, A., Gasparotto, L., Piccoli, M., Taiani, J., ... Sartore, S. (2007). Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryo-injured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells. *The Journal of Urology*, 177(1), 369–376. <http://doi.org/10.1016/j.juro.2006.09.103>
- De Coppi, P., Pozzobon, M., Piccoli, M., Gazzola, M. V., Boldrin, L., Slanzi, E., ... Gamba, P. (2006). Isolation of mesenchymal stem cells from human vermiform appendix. *The Journal of Surgical Research*, 135(1), 85–91. <http://doi.org/10.1016/j.jss.2006.03.009>
- DeKoninck, P., Toelen, J., Zia, S., Albersen, M., Lories, R., Coppi, P. De, & Deprest, J. (2014). Routine isolation and expansion late mid trimester amniotic fluid derived mesenchymal stem cells in a cohort of fetuses with congenital diaphragmatic hernia. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, 178, 157–62. <http://doi.org/10.1016/j.ejogrb.2014.04.007>
- Ditadi, A., de Coppi, P., Picone, O., Gautreau, L., Smati, R., Six, E., ... André-Schmutz, I. (2009). Human and murine amniotic fluid c-Kit+Lin- cells display hematopoietic activity. *Blood*, 113(17), 3953–3960. <http://doi.org/10.1182/blood-2008-10-182105>

Divya, M. S., Roshin, G. E., Divya, T. S., Rasheed, V. A., Santhoshkumar, T. R., Elizabeth, K. E., ... Pillai, R. M. (2012). Umbilical cord blood-derived mesenchymal stem cells consist of a unique population of progenitors co-expressing mesenchymal stem cell and neuronal markers capable of instantaneous neuronal differentiation. *Stem Cell Research & Therapy*, 3(6), 57. <http://doi.org/10.1186/scrt148>

Dormady, S. P., Bashayan, O., Dougherty, R., Zhang, X. M., & Basch, R. S. (2001). Immortalized multipotential mesenchymal cells and the hematopoietic microenvironment. *Journal of Hematotherapy & Stem Cell Research*, 10(1), 125–140. <http://doi.org/10.1089/152581601750098372>

Dormont, D. (1999). Transmissible spongiform encephalopathy agents and animal sera. *Developments in Biological Standardization*, 99, 25–34. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/10404872>

Duscher, D., Rennert, R. C., Januszyk, M., Anghel, E., Maan, Z. N., Whittam, A. J., ... Gurtner, G. C. (2014). Aging disrupts cell subpopulation dynamics and diminishes the function of mesenchymal stem cells. *Scientific Reports*, 4, 7144. <http://doi.org/10.1038/srep07144>

Eliopoulos, N., Stagg, J., Lejeune, L., Pomme, S., & Galipeau, J. (2005). Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. *Blood*, 106(13), 4057–4065. <http://doi.org/10.1182/blood-2005-03-1004>

Eloit, M. (1999). Risks of virus transmission associated with animal sera or substitutes and methods of control. *Developments in Biological Standardization*, 99, 9–16. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/10404870>

Fanjun, C., Ping, Z., Handong, Y., Zhengtong, Y., & Zhaodong, Z. (2003). Induced differentiation of human cord blood mesenchymal stem/progenitor cells into cardiomyocyte-like cells in vitro. *Journal of Huazhong University of Science and Technology [Medical Sciences]*, 23(2), 154–157. <http://doi.org/10.1007/BF02859942>

Fernandez-Moure, J. S., Corradetti, B., Janecek, T., Van Eps, J., Burn, M., Weiner, B. K., ... & Tasciotti, E. (2016). Characterization of Mesenchymal Stem Cells from Human Cortical Bone. *International Journal of Translational Science*, 2016(1), 71-86. <https://doi.org/10.13052/ijts2246-8765.2016.005>

Fisher-Shoval, Y., Barhum, Y., Sadan, O., Yust-Katz, S., Ben-Zur, T., Lev, N., ... Offen, D. (2012). Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS. *Journal of Molecular Neuroscience*, 48(1), 176–184. <http://doi.org/10.1007/s12031-012-9805-6>

Fleming, T. P., Warren, P. D., Chisholm, J. C., & Johnson, M. H. (1984). Trophectodermal processes regulate the expression of totipotency within the inner cell mass of the mouse expanding blastocyst. *Journal of Embryology and Experimental Morphology*, 84, 63–90. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/6533258>

Freeman, B. T., Kouris, N. A., & Ogle, B. M. (2015). Tracking fusion of human mesenchymal stem cells after transplantation to the heart. *Stem Cells Translational Medicine*, 4(6), 685–94. <http://doi.org/10.5966/sctm.2014-0198>

Friedenstein, A. J., Piatetzky-Shapiro, I. I., & Petrakova, K. V. (1966). Osteogenesis in transplants of bone marrow cells. *Journal of Embryology and Experimental Morphology*, 16(3), 381–90. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/5336210>

Fukuhara, S., Tomita, S., Nakatani, T., Ohtsu, Y., Ishida, M., Yutani, C., & Kitamura, S. (2004). G-CSF promotes bone marrow cells to migrate into infarcted mice heart, and differentiate into cardiomyocytes. *Cell Transplantation*, 13(7-8), 741–8. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/15690975>

Fukuhara, S., Tomita, S., Yamashiro, S., Morisaki, T., Yutani, C., Kitamura, S., & Nakatani, T. (2003). Direct cell-cell interaction of cardiomyocytes is key for bone marrow stromal cells to go into cardiac lineage in vitro. *The Journal of Thoracic and Cardiovascular Surgery*, 125(6), 1470–80. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/12830069>

- Gang, E. J., Bosnakovski, D., Figueiredo, C. A., Visser, J. W., & Perlingeiro, R. C. R. (2007). SSEA-4 identifies mesenchymal stem cells from bone marrow. *Blood*, 109(4), 1743–1751. <http://doi.org/10.1182/blood-2005-11-010504>
- Gaziova, I., & Bhat, K. M. (2007). Generating asymmetry: with and without self-renewal. *Progress in Molecular and Subcellular Biology*, 45, 143–78. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/17585500>
- Gerdoni, E., Gallo, B., Casazza, S., Musio, S., Bonanni, I., Pedemonte, E., ... Uccelli, A. (2007). Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. *Annals of Neurology*, 61(3), 219–227. <http://doi.org/10.1002/ana.21076>
- Ghorbani, A., Jalali, S. A., & Varedi, M. (2014). Isolation of adipose tissue mesenchymal stem cells without tissue destruction: a non-enzymatic method. *Tissue & Cell*, 46(1), 54–58. <http://doi.org/10.1016/j.tice.2013.11.002>
- Gnecchi, M., & Melo, L. G. (2009). Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. *Methods in Molecular Biology (Clifton, N.J.)*, 482, 281–294. [http://doi.org/10.1007/978-1-59745-060-7\\_18](http://doi.org/10.1007/978-1-59745-060-7_18)
- Gosden, C. M. (1983). Amniotic fluid cell types and culture. *British Medical Bulletin*, 39(4), 348–54. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/6357346>
- Greco, S. J., Liu, K., & Rameshwar, P. (2007). Functional similarities among genes regulated by OCT4 in human mesenchymal and embryonic stem cells. *Stem Cells (Dayton, Ohio)*, 25(12), 3143–3154. <http://doi.org/10.1634/stemcells.2007-0351>
- Guo, K.-T., SchAfer, R., Paul, A., Gerber, A., Ziemer, G., & Wendel, H. P. (2006). A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. *Stem Cells (Dayton, Ohio)*, 24(10), 2220–2231. <http://doi.org/10.1634/stemcells.2006-0015>

Ho, A. D., Hoffman, R., & Zanjani, E. D. (Eds.). (2006). *Stem Cell Transplantation*. Weinheim, FRG: Wiley-VCH Verlag GmbH & Co. KGaA. <http://doi.org/10.1002/3527608745>

Hoehn, H., & Salk, D. (1982). *Prenatal Diagnosis Cell Biological Approaches. Methods in Cell Biology* (Vol. 26). Elsevier. [http://doi.org/10.1016/S0091-679X\(08\)61362-X](http://doi.org/10.1016/S0091-679X(08)61362-X)

Hong, S. H., Gang, E. J., Jeong, J. A., Ahn, C., Hwang, S. H., Yang, I. H., ... Kim, H. (2005). In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. *Biochemical and Biophysical Research Communications*, 330(4), 1153–1161. <http://doi.org/10.1016/j.bbrc.2005.03.086>

Hoogduijn, M. J., Popp, F., Verbeek, R., Masoodi, M., Nicolaou, A., Baan, C., & Dahlke, M.-H. (2010). The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. *International Immunopharmacology*, 10(12), 1496–1500. <http://doi.org/10.1016/j.intimp.2010.06.019>

Horwitz, E. M., Gordon, P. L., Koo, W. K. K., Marx, J. C., Neel, M. D., McNall, R. Y., ... Hofmann, T. (2002). Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. *Proceedings of the National Academy of Sciences of the United States of America*, 99(13), 8932–8937. <http://doi.org/10.1073/pnas.132252399>

Hristov, M., Erl, W., & Weber, P. C. (2003). Endothelial progenitor cells: isolation and characterization. *Trends in Cardiovascular Medicine*, 13(5), 201–6. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/12837583>

Hung, S.-C., Chen, N.-J., Hsieh, S.-L., Li, H., Ma, H.-L., & Lo, W.-H. (2002). Isolation and characterization of size-sieved stem cells from human bone marrow. *Stem Cells (Dayton, Ohio)*, 20(3), 249–258. <http://doi.org/10.1634/stemcells.20-3-249>

Igura, K., Zhang, X., Takahashi, K., Mitsuru, A., Yamaguchi, S., & Takashi, T. A. (2004). Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. *Cytotherapy*, 6(6), 543–53. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/15770794>

In 't Anker, P. S., Scherjon, S. A., Kleijburg-van der Keur, C., de Groot-Swings, G. M. J. S., Claas, F. H. J., Fibbe, W. E., & Kanhai, H. H. H. (2004). Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. *Stem Cells (Dayton, Ohio)*, 22(7), 1338–1345. <http://doi.org/10.1634/stemcells.2004-0058>

In 't Anker, P. S., Scherjon, S. A., Kleijburg-van der Keur, C., Noort, W. A., Claas, F. H. J., Willemze, R., Kanhai, H. H. H. (2003). Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. *Blood*, 102(4), 1548–1549. <http://doi.org/10.1182/blood-2003-04-1291>

Jang, Y. O., Kim, Y. J., Baik, S. K., Kim, M. Y., Eom, Y. W., Cho, M. Y., ... Kim, Y. M. (2014). Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. *Liver International: Official Journal of the International Association for the Study of the Liver*, 34(1), 33–41. <http://doi.org/10.1111/liv.12218>

Jarvinen, L., Badri, L., Wetlaufer, S., Ohtsuka, T., Standiford, T. J., Toews, G. B., ... Lama, V. N. (2008). Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. *Journal of Immunology (Baltimore, Md. : 1950)*, 181(6), 4389–4396. Retrieved from <http://www.ncbi.nlm.nih.gov/article/fcgi?artid=3644960&tool=pmc&rendertype=abstract>

Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., ... Verfaillie, C. M. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature*, 418(6893), 41–49. <http://doi.org/10.1038/nature00870>

Jiang, Y., Vaessen, B., Lenvik, T., Blackstad, M., Reyes, M., & Verfaillie, C. M. (2002). Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. *Experimental Hematology*, 30(8), 896–904. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/12160841>

- Kaviani, A., Perry, T. E., Dzakovic, A., Jennings, R. W., Ziegler, M. M., & Fauza, D. O. (2001). The amniotic fluid as a source of cells for fetal tissue engineering. *Journal of Pediatric Surgery*, 36(11), 1662–5. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/11685697>
- Kemp, K. C., Hows, J., & Donaldson, C. (2005). Bone marrow-derived mesenchymal stem cells. *Leukemia & Lymphoma*, 46(11), 1531–1544. <http://doi.org/10.1080/10428190500215076>
- Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. *Stem Cells (Dayton, Ohio)*, 24(5), 1294–1301. <http://doi.org/10.1634/stemcells.2005-0342>
- Kim, E. Y., Lee, K.-B., Yu, J., Lee, J. H., Kim, K. J., Han, K.-W., ... Kim, M. K. (2014). Neuronal cell differentiation of mesenchymal stem cells originating from canine amniotic fluid. *Human Cell*, 27(2), 51–58. <http://doi.org/10.1007/s13577-013-0080-9>
- Knoepfler, P. S. (2009). Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. *Stem Cells (Dayton, Ohio)*, 27(5), 1050–1056. <http://doi.org/10.1002/stem.37>
- Koç, O. N., Gerson, S. L., Cooper, B. W., Dyhouse, S. M., Haynesworth, S. E., Caplan, A. I., & Lazarus, H. M. (2000). Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 18(2), 307–16. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/10637244>
- Kögler, G., Sensken, S., Airey, J. A., Trapp, T., Müschen, M., Feldhahn, N., ... Wernet, P. (2004). A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. *The Journal of Experimental Medicine*, 200(2), 123–135. <http://doi.org/10.1084/jem.20040440>

- Krampera, M., Cosmi, L., Angeli, R., Pasini, A., Liotta, F., Andreini, A., ... Annunziato, F. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. *Stem Cells (Dayton, Ohio)*, 24(2), 386–998. <http://doi.org/10.1634/stemcells.2005-0008>
- Kunisaki, S. M., Armant, M., Kao, G. S., Stevenson, K., Kim, H., & Fauza, D. O. (2007). Tissue engineering from human mesenchymal amniocytes: a prelude to clinical trials. *Journal of Pediatric Surgery*, 42(6), 974–980. <http://doi.org/10.1016/j.jpedsurg.2007.01.031>
- Lange, C., Bruns, H., Kluth, D., Zander, A.-R., & Fiegel, H.-C. (2006). Hepatocytic differentiation of mesenchymal stem cells in cocultures with fetal liver cells. *World Journal of Gastroenterology: WJG*, 12(15), 2394–2397. Retrieved from <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1530033/>
- Latifpour, M., Shakiba, Y., Amidi, F., Mazaheri, Z., & Sobhani, A. (2014). Differentiation of human umbilical cord matrix-derived mesenchymal stem cells into germ-like cells. *Avicenna Journal of Medical Biotechnology*, 6(4), 218–227. Retrieved from <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224661/>
- Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., & Ringdén, O. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Experimental Hematology*, 31(10), 890–896. [http://doi.org/10.1016/S0301-472X\(03\)00110-3](http://doi.org/10.1016/S0301-472X(03)00110-3)
- Lee, D.-H., Joo, S.-D., Han, S.-B., Im, J., Lee, S.-H., Sonn, C. H., & Lee, K.-M. (2011). Isolation and expansion of synovial CD34(-)CD44(+)CD90(+) mesenchymal stem cells: comparison of an enzymatic method and a direct explant technique. *Connective Tissue Research*, 52(3), 226–234. <http://doi.org/10.3109/03008207.2010.516850>
- Lee, W.-J., Hah, Y.-S., Ock, S.-A., Lee, J.-H., Jeon, R.-H., Park, J.-S., ... Lee, S.-L. (2015). Cell source-dependent in vivo immunosuppressive properties of mesenchymal stem cells derived from the bone marrow and synovial fluid of minipigs. *Experimental Cell Research*, 333(2), 273–288. <http://doi.org/10.1016/j.yexcr.2015.03.015>

Li, C., Wu, X., Tong, J., Yang, X., Zhao, J., Zheng, Q., ... Ma, Z. (2015). Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy. *Stem Cell Research & Therapy*, 6(1), 55. <http://doi.org/10.1186/s13287-015-0066-5>

Li, L., Wang, D., Zhou, J., Cheng, Y., Liang, T., & Zhang, G. (2015). Characteristics of human amniotic fluid mesenchymal stem cells and their tropism to human ovarian cancer. *PloS One*, 10(4), e0123350. <http://doi.org/10.1371/journal.pone.0123350>

Li, W., Liu, S.-N., Luo, D.-D., Zhao, L., Zeng, L.-L., Zhang, S.-L., & Li, S.-L. (2006). Differentiation of hepatocytoid cell induced from whole-bone-marrow method isolated rat myeloid mesenchymal stem cells. *World Journal of Gastroenterology : WJG*, 12(30), 4866–9. <http://doi.org/10.3748/wjg.v12.i30.4866>

Liu, S., Dontu, G., & Wicha, M. S. (2005). Mammary stem cells, self-renewal pathways, and carcinogenesis. *Breast Cancer Research : BCR*, 7(3), 86–95. <http://doi.org/10.1186/bcr1021>

Lotfy, A., Salama, M., Zahran, F., Jones, E., Badawy, A., & Sobh, M. (2014). Characterization of mesenchymal stem cells derived from rat bone marrow and adipose tissue: a comparative study. *International journal of stem cells*, 7(2), 135. <http://dx.doi.org/10.15283/ijsc.2014.7.2.135> Luz-Crawford, P., Torres, M. J., Noël, D., Fernandez, A., Toupet, K., Alcayaga-Miranda, F., ... Khouri, M. (2016). The immunosuppressive signature of menstrual blood mesenchymal stem cells entails opposite effects on experimental arthritis and graft versus host diseases. *Stem Cells (Dayton, Ohio)*, 34(2), 456–469. <http://doi.org/10.1002/stem.2244>

Makhluf, H. A., Mueller, S. M., Mizuno, S., & Glowacki, J. (2000). Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. *Biochemical and Biophysical Research Communications*, 268(3), 669–72. <http://doi.org/10.1006/bbrc.2000.2182>

Makino, S., Fukuda, K., Miyoshi, S., Konishi, F., Kodama, H., Pan, J., ... Ogawa, S. (1999). Cardiomyocytes can be generated from marrow stromal cells in vitro. *The Journal of Clinical Investigation*, 103(5), 697–705. <http://doi.org/10.1172/JCI5298>

Malgieri, A., Kantzari, E., Patrizi, M. P., & Gambardella, S. (2010). Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. *International Journal of Clinical and Experimental Medicine*, 3(4), 248–269. Retrieved from <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971538/>

Marquez-Curtis, L. A., Janowska-Wieczorek, A., McGann, L. E., & Elliott, J. A. W. (2015). Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects. *Cryobiology*, 71(2), 181–197. <http://doi.org/10.1016/j.cryobiol.2015.07.003>

Martinez, C., Hofmann, T. J., Marino, R., Dominici, M., & Horwitz, E. M. (2007). Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. *Blood*, 109(10), 4245–8. <http://doi.org/10.1182/blood-2006-08-039347>

Matsumoto, T., & Mugishima, H. (2009). Non-hematopoietic stem cells in umbilical cord blood. *International Journal of Stem Cells*, 2(2), 83–9. Retrieved from <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650003/>

Mescher, E. J., Platzker, A. C., Ballard, P. L., Kitterman, J. A., Clements, J. A., & Tooley, W. H. (1975). Ontogeny of tracheal fluid, pulmonary surfactant, and plasma corticoids in the fetal lamb. *Journal of Applied Physiology*, 39(6), 1017–21. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/2573>

Miki, T., & Strom, S. C. (2006). Amnion-derived pluripotent/multipotent stem cells. *Stem Cell Reviews*, 2(2), 133–42. <http://doi.org/10.1007/s12015-006-0020-0>

Mitalipov, S., & Wolf, D. (2009). Totipotency, pluripotency and nuclear reprogramming. *Advances in Biochemical Engineering/biotechnology*, 114, 185–99. [http://doi.org/10.1007/10\\_2008\\_45](http://doi.org/10.1007/10_2008_45)

MR, B. E., Sh, J., & N, A. (2010). Comparison of Proliferation, Senescence and Differentiation into Skeletal Cell Lineages of Murine Bone Marrow-Derived and Amniotic Fluid Mesenchymal Stem Cells. *Iranian Red Crescent Medical Journal*, 2010(Volume 12, Issue 6), 615–623. Retrieved from <http://ircmj.com/328.fulltext>

Mueller, S. M., & Glowacki, J. (2001). Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. *Journal of Cellular Biochemistry*, 82(4), 583–90. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/11500936>

Murrell, W., Féron, F., Wetzig, A., Cameron, N., Splatt, K., Bellette, B., ... Mackay-Sim, A. (2005). Multipotent stem cells from adult olfactory mucosa. *Developmental Dynamics : An Official Publication of the American Association of Anatomists*, 233(2), 496–515. <http://doi.org/10.1002/dvdy.20360>

Nadri, S., & Soleimani, M. (2007). Comparative analysis of mesenchymal stromal cells from murine bone marrow and amniotic fluid. *Cytotherapy*, 9(8), 729–737. <http://doi.org/10.1080/14653240701656061>

Nishimori, M., Yakushiji, H., Mori, M., Miyamoto, T., Yaguchi, T., Ohno, S., ... Ohno, E. (2014). Tumorigenesis in cells derived from induced pluripotent stem cells. *Human Cell*, 27(1), 29–35. <http://doi.org/10.1007/s13577-013-0078-3>

Okita, K., Ichisaka, T., & Yamanaka, S. (2007). Generation of germline-competent induced pluripotent stem cells. *Nature*, 448(7151), 313–7. <http://doi.org/10.1038/nature05934>

Okolicsanyi, R. K., Camilleri, E. T., Oikari, L. E., Yu, C., Cool, S. M., van Wijnen, A. J., ... Haupt, L. M. (2015). Human Mesenchymal Stem Cells Retain Multilineage Differentiation Capacity Including Neural Marker Expression after Extended In Vitro Expansion. *PloS One*, 10(9), e0137255. <http://doi.org/10.1371/journal.pone.0137255>

Ong, S.-Y., Dai, H., & Leong, K. W. (2006). Inducing hepatic differentiation of human mesenchymal stem cells in pellet culture. *Biomaterials*, 27(22), 4087–97. <http://doi.org/10.1016/j.biomaterials.2006.03.022>

Orozco, L., Munar, A., Soler, R., Alberca, M., Soler, F., Huguet, M., ... García-Sancho, J. (2013). Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. *Transplantation*, 95(12), 1535–41. <http://doi.org/10.1097/TP.0b013e318291a2da>

Orozco, L., Soler, R., Morera, C., Alberca, M., Sánchez, A., & García-Sancho, J. (2011). Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. *Transplantation*, 92(7), 822–8. <http://doi.org/10.1097/TP.0b013e3182298a15>

Peng, H.-H., Wang, T.-H., Chao, A.-S., & Chang, S.-D. (2007). Isolation and differentiation of human mesenchymal stem cells obtained from second trimester amniotic fluid; experiments at Chang Gung Memorial Hospital. *Chang Gung Medical Journal*, 30, 402–407.

Perin, L., Sedrakyan, S., Da Sacco, S., & De Filippo, R. (2008). Characterization of human amniotic fluid stem cells and their pluripotential capability. *Methods in Cell Biology*, 86, 85–99. [http://doi.org/10.1016/S0091-679X\(08\)00005-8](http://doi.org/10.1016/S0091-679X(08)00005-8)

Phelan, K. and May, K.M. 2017. Mammalian cell tissue culture techniques. Current Protocols in Molecular Biology 117:A.3F.1-A.3F.23. doi: 10.1002/cpmb.31

Pieri, F., Lucarelli, E., Corinaldesi, G., Fini, M., Aldini, N. N., Giardino, R., ... Marchetti, C. (2009). Effect of mesenchymal stem cells and platelet-rich plasma on the healing of standardized bone defects in the alveolar ridge: a comparative histomorphometric study in minipigs. *Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons*, 67(2), 265–272. <http://doi.org/10.1016/j.joms.2008.06.036>

Pisciotta, A., Carnevale, G., Meloni, S., Riccio, M., De Biasi, S., Gibellini, L., ... De Pol, A. (2015). Human dental pulp stem cells (hDPSCs): isolation, enrichment and comparative differentiation of two sub-populations. *BMC Developmental Biology*, 15(1), 14. <http://doi.org/10.1186/s12861-015-0065-x>

Pittenger, M. F. (1999a). Multilineage Potential of Adult Human Mesenchymal Stem Cells. *Science*, 284(5411), 143–147. <http://doi.org/10.1126/science.284.5411.143>

Pittenger, M. F. (1999b). Multilineage Potential of Adult Human Mesenchymal Stem Cells. *Science*, 284(5411), 143–147. <http://doi.org/10.1126/science.284.5411.143>

Price, P. J., & Gregory, E. A. (1982). Relationship between in vitro growth promotion and biophysical and biochemical properties of the serum supplement. *In Vitro*, 18(6), 576–584. <http://doi.org/10.1007/BF02810081>

Ramachandra, D. L., Shaw, S. S. W., Shangaris, P., Loukogeorgakis, S., Guillot, P. V, Coppi, P. De, & David, A. L. (2014). In utero therapy for congenital disorders using amniotic fluid stem cells. *Frontiers in Pharmacology*, 5, 270. <http://doi.org/10.3389/fphar.2014.00270>

Rangappa, S., Fen, C., Lee, E. H., Bongso, A., Sim, E. K. W., & Wei, E. K. S. (2003). Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. *The Annals of Thoracic Surgery*, 75(3), 775–9. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/12645692>

Ringdén, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lönnies, H., ... Le Blanc, K. (2006). Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. *Transplantation*, 81(10), 1390–7. <http://doi.org/10.1097/01.tp.0000214462.63943.14>

Roemeling-van Rhijn, M., Reinders, M. E. J., de Klein, A., Douben, H., Korevaar, S. S., Mensah, F. K. F., ... Hoogduijn, M. J. (2012). Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. *Kidney International*, 82(7), 748–758. <http://doi.org/10.1038/ki.2012.187>

Roubelakis, M. G., Pappa, K. I., Bitsika, V., Zagoura, D., Vlahou, A., Papadaki, H. A., ... Anagnou, N. P. (2007). Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. *Stem Cells and Development*, 16(6), 931–952. <http://doi.org/10.1089/scd.2007.0036>

Roubelakis, M. G., Trohatou, O., Roubelakis, A., Mili, E., Kalaitzopoulos, I., Papazoglou, G., ... Anagnou, N. P. (2014). Platelet-rich plasma (PRP) promotes fetal mesenchymal stem/stromal cell migration and wound healing process. *Stem Cell Reviews*, 10(3), 417–28. <http://doi.org/10.1007/s12015-013-9494-8>

Sabapathy, V., Sundaram, B., V M, S., Mankuzhy, P., & Kumar, S. (2014). Human Wharton's Jelly Mesenchymal Stem Cells plasticity augments scar-free skin wound healing with hair growth. *PLoS One*, 9(4), e93726. <http://doi.org/10.1371/journal.pone.0093726>

Sahraian, M. A., Mohyeddin Bonab, M., Ahmadi Karvigh, S., Yazdanbakhsh, S., Nikbin, B., & Lotfi, J. (2013). Intrathecal Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Follow-Up Study for Five Years After Injection. *Archives of Neuroscience*, 1(2), 71–75. <http://doi.org/10.5812/archneurosci.13687>

Sarugaser, R., Lickorish, D., Baksh, D., Hosseini, M. M., & Davies, J. E. (2005). Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. *Stem Cells (Dayton, Ohio)*, 23(2), 220–229. <http://doi.org/10.1634/stemcells.2004-0166>

Schieker, M., Pautke, C., Reitz, K., Hemraj, I., Neth, P., Mutschler, W., & Milz, S. (2004). The use of four-colour immunofluorescence techniques to identify mesenchymal stem cells. *Journal of Anatomy*, 204(2), 133–139. <http://doi.org/10.1111/j.1469-7580.2004.00252.x>

Schmidt, D., Achermann, J., Odermatt, B., Breymann, C., Mol, A., Genoni, M., ... Hoerstrup, S. P. (2007). Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source. *Circulation*, 116(11 Suppl), I64–70. <http://doi.org/10.1161/CIRCULATIONAHA.106.681494>

Schrepfer, S., Deuse, T., Lange, C., Katzenberg, R., Reichenspurner, H., Robbins, R. C., & Pelletier, M. P. (2007). Simplified protocol to isolate, purify, and culture expand mesenchymal stem cells. *Stem Cells and Development*, 16(1), 105–7. <http://doi.org/10.1089/scd.2006.0041>

Schüring, A. N., Schulte, N., Kelsch, R., Röpke, A., Kiesel, L., & Götte, M. (2011). Characterization of endometrial mesenchymal stem-like cells obtained by endometrial biopsy during routine diagnostics. *Fertility and Sterility*, 95(1), 423–426. <http://doi.org/10.1016/j.fertnstert.2010.08.035>

- Sessarego, N., Parodi, A., Podestà, M., Benvenuto, F., Mogni, M., Raviolo, V., ... Frassoni, F. (2008). Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. *Haematologica*, 93(3), 339–346. <http://doi.org/10.3324/haematol.11869>
- Shafa, M., Sjønnesen, K., Yamashita, A., Liu, S., Michalak, M., Kallos, M. S., & Rancourt, D. E. (2012). Expansion and long-term maintenance of induced pluripotent stem cells in stirred suspension bioreactors. *Journal of Tissue Engineering and Regenerative Medicine*, 6(6), 462–472. <http://doi.org/10.1002/jterm.450>
- Shiota, M., Heike, T., Haruyama, M., Baba, S., Tsuchiya, A., Fujino, H., ... Nakahata, T. (2007). Isolation and characterization of bone marrow-derived mesenchymal progenitor cells with myogenic and neuronal properties. *Experimental Cell Research*, 313(5), 1008–1023. <http://doi.org/10.1016/j.yexcr.2006.12.017>
- Sieber-Blum, M., & Hu, Y. (2008). Epidermal neural crest stem cells (EPI-NCSC) and pluripotency. *Stem Cell Reviews*, 4(4), 256–260. <http://doi.org/10.1007/s12015-008-9042-0>
- Silva, W. A., Covas, D. T., Panepucci, R. A., Proto-Siqueira, R., Siufi, J. L. C., Zanette, D. L., ... Zago, M. A. (2003). The profile of gene expression of human marrow mesenchymal stem cells. *Stem Cells (Dayton, Ohio)*, 21(6), 661–669. <http://doi.org/10.1634/stemcells.21-6-661>
- Simoni, G., & Colognato, R. (2009). The amniotic fluid-derived cells: the biomedical challenge for the third millennium. *Journal of Prenatal Medicine*, 3(3), 34–6.
- Simonson, O. E., Domogatskaya, A., Volchkov, P., & Rodin, S. (2015). The safety of human pluripotent stem cells in clinical treatment. *Annals of medicine*, 47(5), 370–380. <https://doi.org/10.3109/07853890.2015.1051579>
- Song, L., & Tuan, R. S. (2004). Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. *FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology*, 18(9), 980–2. <http://doi.org/10.1096/fj.03-1100fje>

Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C., & Moretta, L. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. *Blood*, 107(4), 1484–1490. <http://doi.org/10.1182/blood-2005-07-2775>

Steigman, S. A., & Fauza, D. O. (2007). Isolation of mesenchymal stem cells from amniotic fluid and placenta. *Current Protocols in Stem Cell Biology, Chapter 1*, Unit 1E.2. <http://doi.org/10.1002/9780470151808.sc01e02s1>

Streubel, B., Martucci-Ivessa, G., Fleck, T., & Bittner, R. E. (1996). [In vitro transformation of amniotic cells to muscle cells--background and outlook]. *Wiener Medizinische Wochenschrift* (1946), 146(9-10), 216–7. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/9012220>

Sun, Q., Li, F., Li, H., Chen, R.-H., Gu, Y.-Z., Chen, Y., ... Zhang, X.-G. (2015). Amniotic fluid stem cells provide considerable advantages in epidermal regeneration: B7H4 creates a moderate inflammation microenvironment to promote wound repair. *Scientific Reports*, 5, 11560. <http://doi.org/10.1038/srep11560>

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*, 131(5), 861–872. <http://doi.org/10.1016/j.cell.2007.11.019>

Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*, 126(4), 663–776. <http://doi.org/10.1016/j.cell.2006.07.024>

Torricelli, F., Brizzi, L., Bernabei, P. A., Gheri, G., Di Lollo, S., Nutini, L., ... Cariati, E. Identification of hematopoietic progenitor cells in human amniotic fluid before the 12th week of gestation. *Italian Journal of Anatomy and Embryology = Archivio Italiano Di Anatomia Ed Embriologia*, 98(2), 119–26. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/8239855>

- Tsai, C.-C., Su, P.-F., Huang, Y.-F., Yew, T.-L., & Hung, S.-C. (2012). Oct4 and Nanog directly regulate Dnmt1 to maintain self-renewal and undifferentiated state in mesenchymal stem cells. *Molecular Cell*, 47(2), 169–182. <http://doi.org/10.1016/j.molcel.2012.06.020>
- Tsai, M.-S., Lee, J.-L., Chang, Y.-J., & Hwang, S.-M. (2004a). Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. *Human Reproduction (Oxford, England)*, 19(6), 1450–1456. <http://doi.org/10.1093/humrep/deh279>
- Tsai, M.-S., Lee, J.-L., Chang, Y.-J., & Hwang, S.-M. (2004b). Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. *Human Reproduction (Oxford, England)*, 19(6), 1450–1456. <http://doi.org/10.1093/humrep/deh279>
- Uccelli, A., Pistoia, V., & Moretta, L. (2007). Mesenchymal stem cells: a new strategy for immunosuppression? *Trends in Immunology*, 28(5), 219–226. <http://doi.org/10.1016/j.it.2007.03.001>
- Ulloa-Montoya, F., Verfaillie, C. M., & Hu, W.-S. (2005). Culture systems for pluripotent stem cells. *Journal of Bioscience and Bioengineering*, 100(1), 12–27. <http://doi.org/10.1263/jbb.100.12>
- Underwood, M. A., Gilbert, W. M., & Sherman, M. P. (2005). Amniotic fluid: not just fetal urine anymore. *Journal of Perinatology : Official Journal of the California Perinatal Association*, 25(5), 341–348. <http://doi.org/10.1038/sj.jp.7211290>
- Vadasz, S., Jensen, T., Moncada, C., Girard, E., Zhang, F., Blanchette, A., & Finck, C. (2014). Second and third trimester amniotic fluid mesenchymal stem cells can repopulate a de-cellularized lung scaffold and express lung markers. *Journal of Pediatric Surgery*, 49(11), 1554–63. <http://doi.org/10.1016/j.jpedsurg.2014.04.006>
- van der Flier, L. G., & Clevers, H. (2009). Stem cells, self-renewal, and differentiation in the intestinal epithelium. *Annual Review of Physiology*, 71, 241–60. <http://doi.org/10.1146/annurev.physiol.010908.163145>

- Vellasamy, S., Sandrasaigaran, P., Vidyadarshan, S., George, E., & Ramasamy, R. (2012). Isolation and characterisation of mesenchymal stem cells derived from human placenta tissue. *World Journal of Stem Cells*, 4(6), 53–61. <http://doi.org/10.4252/wjsc.v4.i6.53>
- Wang, H.-S., Hung, S.-C., Peng, S.-T., Huang, C.-C., Wei, H.-M., Guo, Y.-J., ... Chen, C.-C. (2004). Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. *Stem Cells (Dayton, Ohio)*, 22(7), 1330–7. <http://doi.org/10.1634/stemcells.2004-0013>
- Wang, S., Cheng, H., Dai, G., Wang, X., Hua, R., Liu, X., ... An, Y. (2013). Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury. *Brain Research*, 1532, 76–84. <http://doi.org/10.1016/j.brainres.2013.08.001>
- Wang, T.-H., Lee, Y.-S., & Hwang, S.-M. (2011). Transcriptome analysis of common gene expression in human mesenchymal stem cells derived from four different origins. *Methods in Molecular Biology (Clifton, N.J.)*, 698, 405–417. [http://doi.org/10.1007/978-1-60761-999-4\\_29](http://doi.org/10.1007/978-1-60761-999-4_29)
- Wang, Y., Zhang, Z., Chi, Y., Zhang, Q., Xu, F., Yang, Z., ... Han, Z. C. (2013). Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malignant transformation. *Cell Death & Disease*, 4, e950. <http://doi.org/10.1038/cddis.2013.480>
- Wasterlain, A. S., Braun, H. J., & Dragoo, J. L. (2012). Contents and Formulations of Platelet-Rich Plasma. *Operative Techniques in Orthopaedics*, 22(1), 33–42. <http://doi.org/10.1053/j.jot.2011.11.001>
- Wessman, S. J., & Levings, R. L. (1999). Benefits and risks due to animal serum used in cell culture production. *Developments in Biological Standardization*, 99, 3–8. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/10404869>
- Wouters, G., Grossi, S., Mesoraca, A., Bizzoco, D., Mobili, L., Cignini, P., & Giorlandino, C. (2007). Isolation of amniotic fluid-derived mesenchymal stem cells. *Journal of Prenatal Medicine*, 1(3), 39–40. Retrieved from <http://www.ncbi.nlm.nih.gov/articleinfo.fcgi?artid=3309337&tool=pmcacentrez&rendertype=abstract>

Wu, K.-H., Sheu, J.-N., Wu, H.-P., Tsai, C., Sieber, M., Peng, C.-T., & Chao, Y.-H. (2013). Cotransplantation of umbilical cord-derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: a pilot study. *Transplantation*, 95(5), 773–7. <http://doi.org/10.1097/TP.0b013e31827a93dd>

Xiang, Y., Zheng, Q., Jia, B., Huang, G., Xu, Y., Wang, J., & Pan, Z. (2007). Ex vivo expansion and pluripotential differentiation of cryopreserved human bone marrow mesenchymal stem cells. *Journal of Zhejiang University. Science. B*, 8(2), 136–146. <http://doi.org/10.1631/jzus.2007.B0136>

Xu, J., Fan, W., Tu, X. X., Zhang, T., Hou, Z. J., Guo, T., ... Liu, Q. (2013). Neural ganglioside GD2(+) cells define a subpopulation of mesenchymal stem cells in adult murine bone marrow. *Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology*, 32(4), 889–898. <http://doi.org/10.1159/000354492>

Ying, Q. L., Nichols, J., Chambers, I., & Smith, A. (2003). BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. *Cell*, 115(3), 281–92. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/14636556>

Yoo, J. U., Barthel, T. S., Nishimura, K., Solchaga, L., Caplan, A. I., Goldberg, V. M., & Johnstone, B. (1998). The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells. *The Journal of Bone and Joint Surgery. American Volume*, 80(12), 1745–57. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/9875932>

You, Q., Tong, X., Guan, Y., Zhang, D., Huang, M., Zhang, Y., & Zheng, J. The biological characteristics of human third trimester amniotic fluid stem cells. *The Journal of International Medical Research*, 37(1), 105–12. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/19215679>

Zappia, E., Casazza, S., Pedemonte, E., Benvenuto, F., Bonanni, I., Gerdoni, E., ... Uccelli, A. (2005). Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. *Blood*, 106(5), 1755–61. <http://doi.org/10.1182/blood-2005-04-1496>

Zhang, S., Geng, H., Xie, H., Wu, Q., Ma, X., Zhou, J., & Chen, F. (2010). The heterogeneity of cell subtypes from a primary culture of human amniotic fluid. *Cellular & Molecular Biology Letters*, 15(3), 424–439. <http://doi.org/10.2478/s11658-010-0017-1>

Zhang, Z., Fu, J., Xu, X., Wang, S., Xu, R., Zhao, M., ... Wang, F.-S. (2013). Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. *AIDS (London, England)*, 27(8), 1283–93. <http://doi.org/10.1097/QAD.0b013e32835fab77>

Zhao, P., Ise, H., Hongo, M., Ota, M., Konishi, I., & Nikaido, T. (2005). Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. *Transplantation*, 79(5), 528–35. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/15753841>

Kumar, D., Anand, T., Singh, M. K., Chauhan, M. S., & Manik, R. S. (2009). Characterization of embryonic stem cells: A special focus on farm animals.

Laberge, T., & Cheung, H. S. (2011). *Multipotent dental stem cells: an alternative adult derived stem cell source for regenerative medicine*. INTECH Open Access Publisher.

Korn, B. S., Kikkawa, D. O., & Hicok, K. C. (2009). Identification and characterization of adult stem cells from human orbital adipose tissue. *Ophthalmic Plastic & Reconstructive Surgery*, 25(1), 27–32.

Bindu, H. A., & Srilatha, B. (2011). Potency of various types of stem cells and their transplantation. *J Stem Cell Res Ther*, 1(3).

Savickiene, J., Treigyte, G., Baronaite, S., Valiuliene, G., Kaupinis, A., Valius, M., ... & Navakauskiene, R. (2015). Human amniotic fluid mesenchymal stem cells from second-and third-trimester amniocentesis: differentiation potential, molecular signature, and proteome analysis. *Stem cells international*, 2015.

Takarani, H. M., & Bhajipale, N. S. (2014). Amniotic fluid derived stem cells as an organ specific regenerative medicine: Review.

Zahra, S. A., Muzavir, S. R., Hassan, A., Khan, A. A., & Ahmad, A. (2015). Amniotic Fluid-Derived Stem Cells (AFSC) and Their Application in Cell Therapy and Tissue Engineering. *Razavi International Journal of Medicine*, 3(1).

Lu, Y., Wang, Z., Chen, L., Wang, J., Li, S., Liu, C., & Sun, D. (2018). The in vitro differentiation of GDNF gene-engineered amniotic fluid-derived stem cells into renal tubular epithelial-like cells. *Stem cells and development*, (ja).

Corcelli, M., Hawkins, K., Vlahova, F., Hunjan, A., Dowding, K., Coppi, P., ... & Hristova, M. (2018). Neuroprotection of the hypoxic-ischemic mouse brain by human CD117+ CD90+ CD105+ amniotic fluid stem cells. *Scientific reports*, 8(1), 2425.

Ochiai, D., Masuda, H., Abe, Y., Otani, T., Fukutake, M., Matsumoto, T., ... & Tanaka, M. (2018). Human Amniotic Fluid Stem Cells: Therapeutic Potential for Perinatal Patients with Intractable Neurological Disease. *The Keio journal of medicine*, 2017-0019.

Peng, S. Y., & Shaw, S. W. S. (2018). Prenatal transplantation of human amniotic fluid stem cells for spinal muscular atrophy. *Current Opinion in Obstetrics and Gynecology*, 30(2), 111-115.

Mandatori, D., Penolazzi, L., Pipino, C., Di Tomo, P., Di Silvestre, S., Di Pietro, N., ... & Pandolfi, A. (2018). Menaquinone-4 enhances osteogenic potential of human amniotic fluid mesenchymal stem cells cultured in 2D and 3D dynamic culture systems. *Journal of tissue engineering and regenerative medicine*, 12(2), 447-459.